IMPACT OF DIABETES ON LONG-TERM OUTCOMES IN STEMI PATIENTS UNDERGOING PRIMARY ANGIOPLASTY WITH GLYCOPROTEIN IIB-IIIA INHIBITORS AND BARE METAL STENTS (BMS) OR DRUG-ELUTING STENTS (DES)
DOI:
https://doi.org/10.54112/bcsrj.v2023i1.291Keywords:
diabetes, Drug-eluting stents, Major-adverse-cardiac-events, Target Vessel RevascularizationAbstract
This study aimed to investigate the impact of diabetes on long-term outcomes in STEMI patients undergoing primary angioplasty with glycoprotein IIb/IIIa inhibitors and either BMS or DES. The study was conducted at the interventional cardiology department of HMC and included 278 patients between March 6, 2022, and September 5, 2022. Inclusion criteria were STEMI patients undergoing primary angioplasty, while exclusion criteria were patients with chronic total occlusion, left main disease, and previous PCI or CABG. Data collection was done through chart review and patient follow-up for one year. Diabetic patients had a higher incidence of multivessel disease, and there was a trend towards a higher rate of Major-adverse-cardiac-events (MACE) and Target Vessel Revascularization (TVR) at long-term follow-up. Drug-eluting stents (DES) were associated with a lower TVR incidence than BMS. Our study highlights the negative impact of diabetes on long-term outcomes in STEMI patients undergoing primary angioplasty with glycoprotein IIb/IIIa inhibitors and either BMS or DES. Further studies are needed to confirm these findings and explore potential mechanisms underlying the adverse cardiovascular outcomes in diabetic patients with STEMI. Ultimately, improving the care of diabetic patients with STEMI is critical to reducing morbidity and mortality in this high-risk population.
Downloads
References
Jia H, Liu Y, Wang Z, et al. Impact of diabetes mellitus on clinical outcomes in patients with acute myocardial infarction receiving percutaneous coronary intervention: a meta-analysis. Sci Rep. 2017;7:10687.
Mehran R, Dangas GD, Kobayashi Y, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol. 2004;43(8):1348-1354.
Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619.
Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346(13):957-966.
Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353-1363.
De Luca, G., Sauro, R., Varricchio, A. et al. Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES. J Thromb Thrombolysis 30, 133–141 (2010). https://doi.org/10.1007/s11239-009-0420-5
Porter A, Assali AR, Zahalka A, Iakobishvili Z, Brosh D, Lev EI, Mager A, Battler A, Kornowski R, Hasdai D (2008) Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus. Am Heart J 155(2):284–289
Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA (2001) Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 79:207–214
Giuseppe De Luca; Rosario Sauro; Attilio Varricchio; Michele Capasso; Tonino Lanzillo; Fiore Manganelli; Ciro Mariello; Francesco Siano; Giannignazio Carbone; Maria Rosaria Pagliuca; Giuseppe Rosato; Emilio Di Lorenzo (2010). Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES. , 30(2), 133–141. doi:10.1007/s11239-009-0420-5
De Luca G, Suryapranata H, Stone GW, Antoniucci D, BiondiZoccai G, Kastrati A, Chiariello M, Marino P (2008) Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 126:37–44
De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW; DESERT cooperation. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care. 2013 Apr;36(4):1020-5. doi: 10.2337/dc12-1507. Epub 2012 Dec 28. PMID: 23275351; PMCID: PMC3609523.
Timmer JR, van der Horst IC, de Luca G, et al.Zwolle Myocardial Infarction Study Group Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005;95:1375–1377
Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866–1873
Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;29
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 RD KHAN, S MAQSOOD, MA KHAN, N ALI , IU KHAN, Z AHMAD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
